• CHMP recommend white blood cell growth stimulator biosimilar to EMA pharmafile
    July 31, 2018
    The European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of two separate biosimilar versions of California-based biopharmaceutical company, Amgen’s Neulasta (pegfilgrastim).
PharmaSources Customer Service